{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:22:22Z","timestamp":1784042542351,"version":"3.55.0"},"reference-count":106,"publisher":"Xia & He Publishing","issue":"X","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,28]]},"DOI":"10.14218\/jcth.2018.00057","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T05:13:17Z","timestamp":1561698797000},"page":"1-11","source":"Crossref","is-referenced-by-count":27,"title":["Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants"],"prefix":"10.14218","volume":"7","author":[{"given":"Matthew","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"key20190628051311_b1","first-page":"589","article-title":"Case of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of the portal vein","volume":"14","author":"Balfour","year":"1869","journal-title":"Edinb Med J"},{"key":"key20190628051311_b2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cld.679","article-title":"Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis","volume":"10","author":"Young","year":"2018","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"key20190628051311_b3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000369896","article-title":"Clinical management of acute portal\/mesenteric vein thrombosis","volume":"30","author":"Lang","year":"2014","journal-title":"Viszeralmedizin"},{"key":"key20190628051311_b4","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"Ageno","year":"2014","journal-title":"Blood"},{"key":"key20190628051311_b5","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(12)70025-7","article-title":"Splanchnic vein thrombosis: new risk factors and management","volume":"129","author":"Donadini","year":"2012","journal-title":"Thromb Res"},{"key":"key20190628051311_b6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J Gastroenterol"},{"key":"key20190628051311_b7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.01.001","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano","year":"2004","journal-title":"J Hepatol"},{"key":"key20190628051311_b8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0016-5085(85)90327-0","article-title":"Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients","volume":"89","author":"Okuda","year":"1985","journal-title":"Gastroenterology"},{"key":"key20190628051311_b9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00000658-198603000-00012","article-title":"Portal thrombosis in cirrhotics. A retrospective analysis","volume":"203","author":"Belli","year":"1986","journal-title":"Ann Surg"},{"key":"key20190628051311_b10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jhep.2011.12.034","article-title":"Portal vein thrombosis, cirrhosis, and liver transplantation","volume":"57","author":"Francoz","year":"2012","journal-title":"J Hepatol"},{"key":"key20190628051311_b11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"key":"key20190628051311_b12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000369987","article-title":"Etiology and complications of portal vein thrombosis","volume":"30","author":"Trebicka","year":"2014","journal-title":"Viszeralmedizin"},{"key":"key20190628051311_b13","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","article-title":"Management of hepatocellular carcinoma with portal vein thrombosis","volume":"21","author":"Quirk","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key20190628051311_b14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"key20190628051311_b15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s004320050189","article-title":"Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study","volume":"124","author":"Pirisi","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20190628051311_b16","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"key20190628051311_b17","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"key20190628051311_b18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1538-7836.2006.02264.x","article-title":"High incidence of concomitant venous thromboembolism in patients with portal vein thrombosis: a population study based on 23 796 consecutive autopsies","volume":"5","author":"Ogren","year":"2007","journal-title":"J Thromb Haemost"},{"key":"key20190628051311_b19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2015-03-631119","article-title":"Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival","volume":"126","author":"S\u00f8gaard","year":"2015","journal-title":"Blood"},{"key":"key20190628051311_b20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/asheducation-2014.1.318","article-title":"Management of incidental splanchnic vein thrombosis in cancer patients","volume":"2014","author":"Kreuziger","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20190628051311_b21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"key20190628051311_b22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/gut.48.1.103","article-title":"Hepatocellular carcinoma in Central Europe: prognostic features and survival","volume":"48","author":"Sch\u00f6niger-Hekele","year":"2001","journal-title":"Gut"},{"key":"key20190628051311_b23","doi-asserted-by":"crossref","first-page":"e112501","DOI":"10.1371\/journal.pone.0112501","article-title":"Rational classification of portal vein thrombosis and its clinical significance","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS One"},{"key":"key20190628051311_b24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2016.08.033","article-title":"Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis","volume":"151","author":"Sarin","year":"2016","journal-title":"Gastroenterology"},{"key":"key20190628051311_b25","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(12)60004-X","article-title":"Management of hepatic vascular diseases","volume":"56","author":"Plessier","year":"2012","journal-title":"J Hepatol"},{"key":"key20190628051311_b26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/hep.23259","article-title":"Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study","volume":"51","author":"Plessier","year":"2010","journal-title":"Hepatology"},{"key":"key20190628051311_b27","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1572-0241.2007.01477.x","article-title":"Prognostic factors in noncirrhotic patients with splanchnic vein thromboses","volume":"102","author":"Amitrano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"key20190628051311_b28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/jhep.2000.16597","article-title":"Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy","volume":"32","author":"Condat","year":"2000","journal-title":"Hepatology"},{"key":"key20190628051311_b29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/qjmed\/93.8.531","article-title":"Clinical features, diagnosis and outcome of acute portal vein thrombosis","volume":"93","author":"Sheen","year":"2000","journal-title":"QJM"},{"key":"key20190628051311_b30","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bjs.6319","article-title":"Epidemiology, risk and prognostic factors in mesenteric venous thrombosis","volume":"95","author":"Acosta","year":"2008","journal-title":"Br J Surg"},{"key":"key20190628051311_b31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-230X-7-34","article-title":"Portal vein thrombosis; risk factors, clinical presentation and treatment","volume":"7","author":"Sogaard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"key20190628051311_b32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"Luca","year":"2012","journal-title":"Radiology"},{"key":"key20190628051311_b33","first-page":"1539","article-title":"Portal vein thrombosis in patients with liver cirrhosis: insights to risk factors, clinical presentation and outcome","volume":"3","author":"Afifi","year":"2015","journal-title":"Int J of Adv Res"},{"key":"key20190628051311_b34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1499-3872(16)60092-9","article-title":"Incidence and clinical presentation of portal vein thrombosis in cirrhotic patients","volume":"15","author":"Cagin","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"key20190628051311_b35","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2214\/ajr.165.5.7572494","article-title":"Cavernous transformation of the portal vein: patterns of intrahepatic and splanchnic collateral circulation detected with Doppler sonography","volume":"165","author":"De Gaetano","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"key20190628051311_b36","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1053\/jhep.2003.50232","article-title":"Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study","volume":"37","author":"Condat","year":"2003","journal-title":"Hepatology"},{"key":"key20190628051311_b37","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1055\/s-0038-1666861","article-title":"Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference","volume":"118","author":"Intagliata","year":"2018","journal-title":"Thromb Haemost"},{"key":"key20190628051311_b38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.dld.2016.11.013","article-title":"Portal vein thrombosis: The role of imaging in the clinical setting","volume":"49","author":"Margini","year":"2017","journal-title":"Dig Liver Dis"},{"key":"key20190628051311_b39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2214\/AJR.04.1218","article-title":"Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems","volume":"186","author":"Rossi","year":"2006","journal-title":"AJR Am J Roentgenol"},{"key":"key20190628051311_b40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00261-005-0150-x","article-title":"Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy","volume":"31","author":"Tarantino","year":"2006","journal-title":"Abdom Imaging"},{"key":"key20190628051311_b41","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.3748\/wjg.v21.i32.9457","article-title":"Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma","volume":"21","author":"Tarantino","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key20190628051311_b42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/hep.20062","article-title":"The hepatic venous pressure gradient: anything worth doing should be done right","volume":"39","author":"Groszmann","year":"2004","journal-title":"Hepatology"},{"key":"key20190628051311_b43","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/jhep.2000.19322","article-title":"The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis","volume":"32","author":"Merkel","year":"2000","journal-title":"Hepatology"},{"key":"key20190628051311_b44","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"key20190628051311_b45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1309\/AJCP7VO4HAIZYATP","article-title":"JAK2 mutations across a spectrum of venous thrombosis cases","volume":"134","author":"Shetty","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"key20190628051311_b46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"key20190628051311_b47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3346\/jkms.2015.30.7.882","article-title":"JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis","volume":"30","author":"Kim","year":"2015","journal-title":"J Korean Med Sci"},{"key":"key20190628051311_b48","first-page":"557","article-title":"CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review","volume":"29","author":"Langabeer","year":"2016","journal-title":"Ann Gastroenterol"},{"key":"key20190628051311_b49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/clinchem\/47.9.1597","article-title":"Laboratory investigation of thrombophilia","volume":"47","author":"Tripodi","year":"2001","journal-title":"Clin Chem"},{"key":"key20190628051311_b50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5045\/br.2014.49.2.85","article-title":"Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants","volume":"49","author":"Nakashima","year":"2014","journal-title":"Blood Res"},{"key":"key20190628051311_b51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/lt.21941","article-title":"Portal vein thrombosis and survival in patients with cirrhosis","volume":"16","author":"Englesbe","year":"2010","journal-title":"Liver Transpl"},{"key":"key20190628051311_b52","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/j.1538-7836.2005.01414.x","article-title":"Treatment of venous thromboembolism","volume":"3","author":"Buller","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key20190628051311_b53","unstructured":"Portal vein thrombosis2018Available from: http:\/\/thrombosiscanada.ca\/wp-content\/uploads\/2018\/02\/Portal-Vein-Thrombosis-2018Jan30.pdf"},{"key":"key20190628051311_b54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"Cui","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20190628051311_b55","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4172\/2376-0419.1000161","article-title":"Monitoring enoxaparin with antifactor Xa levels in severe renal impairment","volume":"3","author":"Vega","year":"2016","journal-title":"J Pharma Care Health Sys"},{"key":"key20190628051311_b56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.13189\/app.2013.010201","article-title":"Analysis of anti-xa concentrations in patients on treatment dose enoxaparin: A retrospective chart review","volume":"1","author":"Levine","year":"2013","journal-title":"Advances in Pharmacology and Pharmacy"},{"key":"key20190628051311_b57","doi-asserted-by":"crossref","first-page":"126975","DOI":"10.1155\/2015\/126975","article-title":"Clinical use of anti-Xa monitoring in malignancy-associated thrombosis","volume":"2015","author":"Yentz","year":"2015","journal-title":"Thrombosis"},{"key":"key20190628051311_b58","first-page":"33","article-title":"Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review","volume":"68","author":"Egan","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"key20190628051311_b59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/asheducation-2016.1.206","article-title":"Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer","volume":"2016","author":"Kreuziger","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20190628051311_b60","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.3390\/jcm7020029","article-title":"A practical review of the emerging direct anticoagulants, laboratory monitoring, and reversal agents","volume":"7","author":"Joppa","year":"2018","journal-title":"J Clin Med"},{"key":"key20190628051311_b61","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"key":"key20190628051311_b62","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"key20190628051311_b63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"key20190628051311_b64","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"key20190628051311_b65","unstructured":"FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patientsAvailable from: http:\/\/www.crtonline.org\/news-detail\/fda-approved-betrixaban-bevyxxa-portola-prophylaxi"},{"key":"key20190628051311_b66","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/01.RVI.0000156265.79960.86","article-title":"Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis","volume":"16","author":"Hollingshead","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"key20190628051311_b67","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jvs.2012.04.024","article-title":"Direct thrombolytic therapy in portal and mesenteric vein thrombosis","volume":"56","author":"Chen","year":"2012","journal-title":"J Vasc Surg"},{"key":"key20190628051311_b68","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.dld.2017.05.020","article-title":"Transjugular local thrombolysis with\/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis","volume":"49","author":"Klinger","year":"2017","journal-title":"Dig Liver Dis"},{"key":"key20190628051311_b69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-0034-1382790","article-title":"Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up","volume":"31","author":"Copelan","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"key20190628051311_b70","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.28429","article-title":"Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization","volume":"63","author":"Kallini","year":"2016","journal-title":"Hepatology"},{"key":"key20190628051311_b71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00270-017-1756-4","article-title":"Trans-splenic access for portal venous interventions in children: Do benefits outweigh risks?","volume":"41","author":"Pimpalwar","year":"2018","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key20190628051311_b72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1148\/radiology.195.1.7892458","article-title":"Noncavernomatous portal vein thrombosis in hepatic cirrhosis: treatment with transjugular intrahepatic portosystemic shunt and local thrombolysis","volume":"195","author":"Blum","year":"1995","journal-title":"Radiology"},{"key":"key20190628051311_b73","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/gutjnl-2011-300577","article-title":"Transjugular intrahepatic portosystemic shunt for portal vein thrombosis in cirrhosis","volume":"61","author":"Han","year":"2012","journal-title":"Gut"},{"key":"key20190628051311_b74","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s12072-011-9324-5","article-title":"Transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis: a critical review of literature","volume":"6","author":"Qi","year":"2012","journal-title":"Hepatol Int"},{"key":"key20190628051311_b75","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.22772","article-title":"Vascular disorders of the liver","volume":"49","author":"DeLeve","year":"2009","journal-title":"Hepatology"},{"key":"key20190628051311_b76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"Clinical Practice Guidelines: Vascular diseases of the liver.","volume":"64","author":"EASL","year":"2016","journal-title":"J. Hepatol"},{"key":"key20190628051311_b77","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"key20190628051311_b78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2012.09249.x","article-title":"Guidelines on the investigation and management of venous thrombosis at unusual sites","volume":"159","author":"Tait","year":"2012","journal-title":"Br J Haematol"},{"key":"key20190628051311_b79","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11239-015-1308-1","article-title":"Guidance for the management of venous thrombosis in unusual sites","volume":"41","author":"Ageno","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"key20190628051311_b80","unstructured":"NCCN Guidelines: Cancer-associated venous thromboembolic diseaseAvailable from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf"},{"key":"key20190628051311_b81","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20190628051311_b82","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.6004\/jnccn.2013.0163","article-title":"Venous thromboembolic disease","volume":"11","author":"Streiff","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"key20190628051311_b83","doi-asserted-by":"crossref","first-page":"480842","DOI":"10.1155\/2015\/480842","article-title":"Association between portal vein thrombosis and survival in non-liver-transplant patients with liver cirrhosis: A systematic review of the literature","volume":"2015","author":"Qi","year":"2015","journal-title":"Gastroenterol Res Pract"},{"key":"key20190628051311_b84","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/ajg.2012.313","article-title":"The effectiveness of current acute variceal bleed treatments in unselected cirrhotic patients: refining short-term prognosis and risk factors","volume":"107","author":"Amitrano","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key20190628051311_b85","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/jhep.2003.50385","article-title":"Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators","volume":"38","author":"D\u2019Amico","year":"2003","journal-title":"Hepatology"},{"key":"key20190628051311_b86","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"key20190628051311_b87","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","article-title":"Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function","volume":"130","author":"Scheiner","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"key20190628051311_b88","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"key20190628051311_b89","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20190628051311_b90","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"key":"key20190628051311_b91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"key":"key20190628051311_b92","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"key20190628051311_b93","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3350\/cmh.2016.0016","article-title":"Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"key20190628051311_b94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.26998","article-title":"Treatment of acute portal vein thrombosis by nontraditional anticoagulation","volume":"60","author":"Martinez","year":"2014","journal-title":"Hepatology"},{"key":"key20190628051311_b95","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1055\/s-0034-1385171","article-title":"Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban","volume":"52","author":"Lenz","year":"2014","journal-title":"Z Gastroenterol"},{"key":"key20190628051311_b96","doi-asserted-by":"crossref","first-page":"8432781","DOI":"10.1155\/2018\/8432781","article-title":"Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis","volume":"2018","author":"Priyanka","year":"2018","journal-title":"Int J Hepatol"},{"key":"key20190628051311_b97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5811\/westjem.2016.3.29294","article-title":"Anticoagulation reversal and treatment strategies in major bleeding: Update 2016","volume":"17","author":"Christos","year":"2016","journal-title":"West J Emerg Med"},{"key":"key20190628051311_b98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"key20190628051311_b99","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"key20190628051311_b100","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"key20190628051311_b101","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12876-017-0668-8","article-title":"Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome","volume":"17","author":"Fujiyama","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"key20190628051311_b102","first-page":"208","article-title":"Risk factors stratifications for portal venous thrombosis (PVT)","volume":"6","author":"Al-Azzawi","year":"2017","journal-title":"J Liver"},{"key":"key20190628051311_b103","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1160\/TH07-08-0526","article-title":"Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis","volume":"99","author":"Dentali","year":"2008","journal-title":"Thromb Haemost"},{"key":"key20190628051311_b104","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.clinthera.2018.10.009","article-title":"A review of the efficacy and safety profiles of the novel oral anticoagulants in the treatment and prevention of venous thromboembolism","volume":"40","author":"Coulis","year":"2018","journal-title":"Clin Ther"},{"key":"key20190628051311_b105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ccm.2018.04.010","article-title":"An update on the \u201cnovel\u201d and direct oral anticoagulants, and long-term anticoagulant therapy","volume":"39","author":"Djulbegovic","year":"2018","journal-title":"Clin Chest Med"},{"key":"key20190628051311_b106","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2018.00057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:17:34Z","timestamp":1783707454000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2018.00057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":106,"journal-issue":{"issue":"X","published-online":{"date-parts":[[2019,6,28]]},"published-print":{"date-parts":[[2019,6,28]]}},"alternative-id":["10.14218\/JCTH.2018.00057"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2018.00057","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]}}}